Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) Upgraded by Barclays to “Strong-Buy” Rating

Barclays upgraded shares of Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) to a strong-buy rating in a research report sent to investors on Wednesday,Zacks.com reports.

Swedish Orphan Biovitrum AB (publ) Price Performance

Shares of BIOVF opened at $28.30 on Wednesday. The company’s 50-day simple moving average is $28.88 and its 200-day simple moving average is $28.35. The company has a debt-to-equity ratio of 0.30, a quick ratio of 0.49 and a current ratio of 0.73. Swedish Orphan Biovitrum AB has a 1 year low of $22.87 and a 1 year high of $32.25. The stock has a market capitalization of $10.07 billion, a PE ratio of 47.97 and a beta of 0.51.

About Swedish Orphan Biovitrum AB (publ)

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still’s disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection.